Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity
about
Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer ImmunotherapyRelevance of tumor-infiltrating lymphocytes in breast cancerImmune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With ImmunotherapyImmunotherapy advances for glioblastomaHarnessing immunosurveillance: current developments and future directions in cancer immunotherapyImmune Checkpoint in Glioblastoma: Promising and ChallengingThe "Trojan Horse" approach to tumor immunotherapy: targeting the tumor microenvironment.Neoadjuvant anti-tumor vaccination prior to surgery enhances survival.Chemotherapy enhances cross-presentation of nuclear tumor antigensThe efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40Effect of cytotoxic T-lymphocyte antigen-4, TNF-alpha polymorphisms on osteosarcoma: evidences from a meta-analysis.Targeting the inhibitory receptor CTLA-4 on T cells increased abscopal effects in murine mesothelioma model.Network analysis of immunotherapy-induced regressing tumours identifies novel synergistic drug combinations.Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.Pancreatic Cancer: Progress in Systemic Therapy.Strategies and developments of immunotherapies in osteosarcomaHuman mesothelioma induces defects in dendritic cell numbers and antigen-processing function which predict survival outcomesPhase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma.Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models.Immunotherapy following regional chemotherapy treatment of advanced extremity melanomaRecent technological advances in using mouse models to study ovarian cancer.Immunotherapy for malignant pleural mesothelioma. Current status and future prospects.What is the role of chemotherapy in the treatment of melanoma?Potential approaches for more successful dendritic cell-based immunotherapy.Immune response profiling of malignant pleural mesothelioma for diagnostic and prognostic biomarkers.Breast cancer and immunology: biomarker and therapeutic developments.Adjuvant Therapy with Silibinin Improves the Efficacy of Paclitaxel and Cisplatin in MCF-7 Breast Cancer CellsImpact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth.Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma.Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity.Immunotherapy for malignant mesothelioma: Reality check.DNA Damage and Repair Biomarkers of Immunotherapy Response.Restoration of defective cross-presentation in tumors by gemcitabine.Contrasting effects of cyclophosphamide on anti-CTL-associated protein 4 blockade therapy in two mouse tumor models.A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice.Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy.Checkpoint blockade in solid tumors and B-cell malignancies, with special consideration of the role of CD200.Combining DNA damaging therapeutics with immunotherapy: more haste, less speed.A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer.Phosphoinositide 3-kinase δ inhibition promotes antitumor responses but antagonizes checkpoint inhibitors.
P2860
Q26779184-E5C7653D-60ED-4916-B43C-DD5BC9ADE51FQ26795598-67062AD5-915A-404B-AB3D-C42D67EA0F2DQ26796309-63ECA8DC-10A4-4BCC-A970-04A273310DFAQ26866513-C8E17FE9-7432-44BA-B5FA-D35F141E0B0BQ27021570-CBF5CF5F-6FA7-4EB8-8FC0-DB5C7282894BQ33650058-3BAB17F8-BEE1-48CA-8D42-D2B17728F3CEQ33736218-C1D2F8C5-9F08-418E-B040-304290FB42D9Q34145877-4DEF3DCF-5C8A-4F34-AEBF-59F9CD25BB3CQ34226903-6A66B865-BA81-4381-BDCC-681BDD864DC5Q35060384-D7465ABD-9B1D-4D26-A022-155770F202EEQ35079792-96B30B7B-AF63-4317-B2AB-4D71015980F3Q35828606-4E494954-9013-43C7-8A7F-7F42E9742596Q35869292-9AFF25A9-8621-449D-9B68-E7CDD10EC759Q36293343-D45019D7-980D-4E03-81B2-CABFACB3FD0EQ36344551-6E04325D-DB59-48FF-B6F0-0CB955E9C857Q36503128-4B208D1B-51FB-436E-BE5E-023B6E1A864AQ36711060-BD76379E-DFEB-487A-9923-8139B1337CD1Q36934332-1F6B8BE7-B4BB-4C8E-A9F6-BCFE3D0E7025Q37126642-215A8037-EC3D-4CFD-9625-5858C0CBED28Q37509709-0FF805DC-0978-4972-8A7F-F96CFE98F8B9Q37581537-7B0DC72F-B255-472C-940B-DF429772AA17Q38180749-53384737-5177-48C5-A360-EDBC9AF6A1D1Q38193716-3636AE57-2377-4955-B3C1-BFDE19596195Q38305650-2B5EB46C-A153-479A-A780-94F402A857E1Q38449501-5D1542E0-D739-4523-A9EE-50F2682CF9CDQ38584383-9DA2FD55-BB79-4074-BC7E-2FA60DC5D818Q38694126-0E04864D-4F7B-4034-B731-05DE7689C2DEQ38722809-F3B06CD3-3994-4832-AEF2-5D39052F6BD2Q38961442-5FE54C22-813C-4072-96D7-3A2738AAB3F2Q39069273-BDB78DE1-DFDB-462B-825F-9E6F9F0DF201Q39351008-8B0FE574-E09D-49BA-9E24-DAEC0CD41E5DQ39384263-D936BE13-7500-4555-AA0F-8E1A162578D1Q41592003-1D061EF0-822B-46C8-B57A-C0E154BB8E64Q42288675-A126073C-6261-4E8D-932F-332AE3D929F5Q42690847-86658275-91D1-4D7F-9080-62B643C2E8CBQ45775114-987B1C1F-62B9-49C8-AAFE-D2B68F81EAE6Q46971015-379D32EC-84CA-40A3-8A68-30EDDCDAAD89Q47621538-50F73557-F94D-4AF5-B88C-1F523040E080Q52597561-D0A39B41-48F3-4588-AC4D-566842AB30C1Q54976860-324EDE1F-656F-4462-B0F6-50FE37912042
P2860
Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Synergistic effect of CTLA-4 b ...... duction of anti-tumor immunity
@ast
Synergistic effect of CTLA-4 b ...... duction of anti-tumor immunity
@en
Synergistic effect of CTLA-4 b ...... duction of anti-tumor immunity
@nl
type
label
Synergistic effect of CTLA-4 b ...... duction of anti-tumor immunity
@ast
Synergistic effect of CTLA-4 b ...... duction of anti-tumor immunity
@en
Synergistic effect of CTLA-4 b ...... duction of anti-tumor immunity
@nl
prefLabel
Synergistic effect of CTLA-4 b ...... duction of anti-tumor immunity
@ast
Synergistic effect of CTLA-4 b ...... duction of anti-tumor immunity
@en
Synergistic effect of CTLA-4 b ...... duction of anti-tumor immunity
@nl
P2093
P2860
P1433
P1476
Synergistic effect of CTLA-4 b ...... duction of anti-tumor immunity
@en
P2093
Andrea Khong
Bruce W Robinson
Esdy N Rozali
Ian M Dick
Joanne Salmons
Julie A Harken
Richard A Lake
W Joost Lesterhuis
P2860
P304
P356
10.1371/JOURNAL.PONE.0061895
P407
P577
2013-01-01T00:00:00Z